Market Intelligence, Clinical Progress, and High-Purity Reagents for Urothelial and Solid Tumor ADC Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for Nectin-4 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Nectin-4 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View Nectin-4 Products |
| Gene Delivery | Nectin-4 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Sequence Verified. |
View Nectin-4 Products |
| Benchmark Ab | Anti-Nectin-4 (Sequence of Enfortumab Vedotin) Recombinant positive control for binding, internalization & assay benchmarking. |
View Nectin-4 Products |
| Validator | Nectin-4 siRNA Set For knockdown verification and specificity checks. Sequence Verified. |
View Nectin-4 Products |
| Related Target A | Nectin-1 (PVRL1/CD111) Family counter-screening for selectivity assessment. |
View Nectin-1 Products |
| Related Target B | Nectin-2 / CD112 (PVRL2) Off-target specificity and family panel completeness. |
View Nectin-2 Products |
| Related Target C | Nectin-3 (PVRL3) Selectivity panel component for safety profiling. |
View Nectin-3 Products |
| Related Target D | TROP2 Competing/Synergistic solid tumor ADC target for combination therapy. |
View TROP2 Products |
| Related Target E | HER2 Bypass signaling and ADC efficacy benchmarking. |
View HER2 Products |
Critical Assay Challenges & Solutions
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species Preclinical Evaluation (Cyno/Mouse) | Human, Mouse, and Cynomolgus ortholog Nectin-4 ECD proteins available with >95% purity and strict sequence verification. |
| Glycosylation-dependent Epitope Screening | Expressed exclusively in HEK293 cells to preserve native human post-translational modifications. |
| Lack of Validated ADC Controls | Clinical Benchmark Antibodies (Enfortumab biosimilar sequence) included for internalization and affinity reference. |
| Subfamily Off-target Toxicity (Skin Tox) | Nectin-1, Nectin-2, and Nectin-3 homolog proteins strictly verified by mass spec for counter-screening. |
| ADC Internalization Efficiency | High-purity ECD-Fc with verified conformational epitopes; compatible with pHrodo and Alexa Fluor labeling for FACS/Imaging. |
| High-concentration Stability (Sub-Q Feasibility) | Low-endotoxin (<1EU/ug), aggregation-controlled formulations suitable for viscous formulation screening at >100 mg/mL. |
Live Nectin-4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for Nectin-4 (PVRL4) therapeutics is intensifying, with major players shifting focus from traditional mAbs to Antibody-Drug Conjugates (ADCs) and novel targeted radioligands. Following the tremendous clinical and commercial validation of Enfortumab vedotin in urothelial carcinoma, the global pipeline is aggressively expanding into breast, lung, and pancreatic cancers. As first-generation therapies reach broad clinical adoption, the next wave of R&D is heavily targeting differentiated safety profiles (mitigating skin toxicity), bispecific ADC formats, and overcoming payload resistance via novel linkers and bystander-effect optimization. Combination strategies with checkpoint inhibitors and engineered variants with optimized internalization kinetics are also high-priority areas.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC (First-in-class) | Astellas, Seagen, Pfizer | Urothelial Cancer | Internalization Assay (Need high-purity ECD-Fc & Benchmark Abs) |
| Next-Gen ADC / Bicycle | Bicycle Therapeutics, Kelun-Biotech | Advanced Solid Tumors | Epitope Mapping (Need Nectin-1/2/3 counter-screening panels) |
| Bispecific ADC | Mabwell, Biocytogen | Refractory Carcinomas | Heterodimer Validation (Need High-Purity dual targets e.g., TROP2) |
| Targeted Protein Degraders | Preclinical Biotech | Pancreatic Cancer | Ubiquitination/Degradation Assays (Need sequence-verified siRNAs) |
Nectin-4 Protein Characteristics (UniProt Q96NY8)
Functional Domains:
- Ig-like V-type domain
- Ig-like C2-type 1 domain
- Ig-like C2-type 2 domain
Key Mutations (dbSNP):
- rs3737786 (UniProt VAR_034669)
- rs267606992 (associated with EDSS1; UniProt VAR_064189)
Target Identity: Resolved target: NECTIN4. UniProt Q96NY8 primary entry.